Many participants in HIV-1 vaccine trials. who have not previously been exposed to or vaccinated against HIV-1. display serum immunoglobulin antibodies that bind the gp41 region of HIV-1 envelope prior to vaccination. Previous studies have hypothesized that these pre-existing antibodies may be cross-reactive and may skew future vaccine responses. https://www.chiggate.com/earthbath-facial-wipes-25ct-fashion/